Anti-CD40 agonist antibodies: Preclinical and clinical experience
Update on Cancer Therapeutics · 2007-06 · 2 (2) · 61-65
DOI: 10.1016/j.uct.2007.06.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Update on Cancer Therapeutics, 2007-06. Verfasst von Magi Khalil und 1 weiteren Autor:innen. Beteiligte Einrichtung: Abramson Family Cancer Research Institute; Abramson Cancer Center; Division of Hematology-Oncology, Department of Medicine; University of Pennsylvani…. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Abramson Family Cancer Research Institute; Abramson Cancer Center; Division of Hematology-Oncology, Department of Medicine; University of Pennsylvania School of Medicine, Philadelphia, PA.
Förderung
- NCI NIH HHS
Zitieren
APA
Khalil, M., & Vonderheide, R. H. (2007). Anti-CD40 agonist antibodies: Preclinical and clinical experience. Update on Cancer Therapeutics, 2(2), 61-65. https://doi.org/10.1016/j.uct.2007.06.001
Vancouver
Khalil M, Vonderheide RH. Anti-CD40 agonist antibodies: Preclinical and clinical experience. Update on Cancer Therapeutics. 2007;2(2):61-65. doi:10.1016/j.uct.2007.06.001
BibTeX
@article{Khalil2007,
author = {Khalil, Magi and Vonderheide, Robert H},
title = {Anti-CD40 agonist antibodies: Preclinical and clinical experience},
journal = {Update on Cancer Therapeutics},
year = {2007},
volume = {2},
number = {2},
pages = {61--65},
doi = {10.1016/j.uct.2007.06.001}
}
EUVIMED